Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Japanese Asthma Drug Could Be Effective Treatment for Alcoholism



The small human trial involved 17 males and seven females who reported drinking seven alcoholic beverages per day, at least 21 days out of the month.

Share this!

February 2, 2017 | by Sarah Hand, M.Sc.

A new study conducted by researchers at UCLA, has found that an asthma medication which is only approved in Japan could be an effective treatment option for patients struggling with alcoholism. The study – which was published in the journal, Neuropsychopharmacology – was the first to test the anti-inflammatory drug, ibudilast, in patients with alcoholism.

The small human trial involved 17 males and seven females who reported drinking seven alcoholic beverages per day, at least 21 days out of the month. Patients were randomly assigned to receive an escalating dose of the drug, or a placebo, over a six-day period.

After a two-week rest period, the patient groups were switched to allow placebo participants to receive the drug. According to the study investigators, patients exhibited lower alcohol cravings when they were taking ibudilast, compared to the placebo.

The researchers also noted changes in mood while patients were taking the drug. In one test, the study participants were asked to hold and smell a glass of an alcoholic beverage, but refrain from consuming the drink. Patients taking ibudilast reported better moods, compared to the placebo.

Patients were also given an intravenous dose of alcohol on the sixth day of the study, in order to determine how the drug interacts with alcohol. As patients being treated for alcoholism may still drink, it was important for the researchers to determine whether the drug would be safe in this situation.

“We found that ibudilast is safe and well-tolerated,” said Lara Ray, a UCLA professor of psychology, director of the UCLA Addictions Laboratory and the study's lead author. “This medication can be safely administered, including when people are drinking alcohol.”

The drug also appeared to help participants recover from stressful situations, and benefitted those with depressive symptoms. The researchers also reported that ibudilast may reduce the pleasurable effects of alcohol consumption.

Previous research has shown that ibudilast was effective in rats at reducing alcohol consumption. “We're excited to see that the strong animal data with ibudilast is now followed by our finding that ibudilast is well-tolerated in humans,” said Ray.

To date, the US Food and Drug Administration (FDA) has only approved four treatments for alcoholism, but they are not widely-prescribed. More clinical trials will need to be performed in order to determine whether ibudilast would be effective at treating alcoholism.

Keywords: Anti-inflammatory, Alcoholism, FDA


Share this with your colleagues!

Researchers Identify Role of ApoE4 Gene as Possible Drug Target in Alzheimer’s Disease

September 21, 2017 - A team of neurology researchers at Washington University School of Medicine in St. Louis have found that in the presence of the ApoE4 protein, another protein known as tau forms tangles in the brain which contributes to neuronal damage characteristic of Alzheimer’s disease.

Featured In: Life Science News

New Guidelines Address CAR-T Immunotherapy Toxicities to Prevent Patient Deaths

September 20, 2017 - Clinicians at The University of Texas MD Anderson Cancer Center have published new guidelines in the journal, Nature Reviews Clinical Oncology, which could help in the management of these toxicities.

Featured In: Biotech News, Drug Safety News

Microneedle Skin Patch Could Treat Common Metabolic Disorders

September 19, 2017 - Researchers at Columbia University Medical Center (CUMC) and the University of North Carolina have developed a microneedle skin patch impregnated with a drug capable of converting white fat into calorie-burning brown fat.

Featured In: Medical Device News


Five Reasons Why Toronto is Emerging as a Major Life Sciences Hub


Development and Manufacture of Highly Potent API Drug Products Throughout the Clinical Phases

Innovation through Integration – Providing Next Generation Biomedical Devices and Interconnects

Clinical Payments Case Studies: Improving Efficiency, Cash Management, and Compliance

Why Phase 3 Trials Fail: Oncology Case Studies and Lessons Learned

Copyright © 2016-2017 Honeycomb Worldwide Inc.